Scope and Claims Analysis for U.S. Patent No. 12,344,585 (Hereditary Angioedema Prophylaxis Using a Specific Compound I Bis(Hydrochloride) Crystalline Salt)
U.S. Patent No. 12,344,585 claims a prophylaxis method for hereditary angioedema (HAE) using once-daily oral dosing of a crystalline salt of “Compound I.” The claims are tightly constrained to a bis(hydrochloride) crystalline salt defined by X-ray powder diffraction (XRPD) peak positions at specific 2θ values (with optional peak lists expanding the specificity) and to dose amounts within roughly 125 mg to 175 mg. Dependent claims narrow to discrete dosage endpoints (about 125 mg and about 175 mg) and expand XRPD peak-set requirements, plus additional characterization elements (XRPD “substantially similar” to a figure; thermogravimetric-infrared spectrum substantially as shown in another figure) and HAE subtypes (type I and type II).
Because the claim structure is built around product-defining analytical features (XRPD and TGA-IR) plus a narrow dosage regimen (once daily, 125–175 mg), the core enforcement risk centers on any generic or branded competitor that makes or sells a salt form of Compound I that matches the claimed diffraction fingerprints and dose range.
What is the claim scope of U.S. Patent 12,344,585 and what does it cover exactly?
Featured snippet answer: The patent covers a once-daily oral prophylaxis method for HAE using a crystalline bis(hydrochloride) salt of Compound I, where the salt is defined by specific XRPD peaks at set 2θ values (e.g., 5.3, 9.0, 22.0 ±0.2°), with additional dependent claims requiring larger peak sets and specific analytical fingerprints.
Independent claim 1: the enforcement anchor
Claim 1 requires all of the following elements:
- Method purpose: prophylaxis to prevent attacks of hereditary angioedema.
- Route and frequency: orally administering once a day.
- Dose range: about 125 mg to about 175 mg of a crystalline salt of Compound I.
- Salt identity: the crystalline salt is a bis(hydrochloride) salt.
- Crystalline form definition via XRPD: the XRPD pattern shows peaks at 2θ ±0.2° of:
This claim is not limited to a particular patient demographic beyond being a “subject with hereditary angioedema.” It is also not limited to a particular manufacturing method. The claim’s distinguishing handle is the crystalline salt identity defined by analytical diffraction peaks plus the bis(hydrochloride) stoichiometry and dose regime.
Dependent claims 2–4: dose endpoint locking
- Claim 2 narrows Claim 1 to administration of about 125 mg.
- Claim 3 narrows Claim 1 to administration of about 175 mg.
- Claim 4 preserves the same basic XRPD peak anchors (5.3, 9.0, 22.0) but removes the explicit ±0.2 framing in the recitation (Claim 1 uses “±0.2°”; Claim 4 states exact 2θ values at that precision level). Practically, Claim 4 remains an XRPD-constrained subset.
Dependent claims 5–8: expanded XRPD fingerprint sets
These claims materially increase specificity by requiring additional peaks beyond the three-peak minimum.
- Claim 5 adds peaks (each with the same ±0.2° framing) at:
- 5.3, 9.0, 19.8, 21.2, 22.0, 23.3 (plus the original 5.3, 9.0, 22.0)
- Claim 6 repeats Claim 5’s XRPD requirement set in alternative wording.
- Claim 7 expands further to a larger list:
- 5.3, 9.0, 14.3, 16.2, 19.8, 21.2, 22.0, 23.3, 24.6, 30.3
- Claim 8 repeats Claim 7’s full expanded peak list.
For litigation and freedom-to-operate, these dependent claims matter because they create a tiered claim ladder:
- If an accused crystalline salt fails the broad 3-peak requirement, it should fall out of Claim 1.
- If it meets the 3-peak requirement but not the larger sets, it may still hit Claim 1 but not Claims 5–8.
- If it matches the larger fingerprint sets, it creates exposure under multiple dependent claims simultaneously.
Dependent claims 9–10: “substantially similar” and TGA-IR support
- Claim 9: XRPD pattern is substantially similar to that shown in FIG. 1.
- Claim 10: the crystalline salt has a thermogravimetric-infrared spectrum substantially as shown in FIG. 2.
These clauses broaden enforcement leverage beyond exact peak enumeration. They also introduce interpretive space around “substantially similar,” which can become a measurement- and expert-driven question in infringement and validity.
Dependent claims 11–12: HAE subtype scope
- Claim 11: type I hereditary angioedema.
- Claim 12: type II hereditary angioedema.
These are narrower subpopulations within “hereditary angioedema” and support clinical labeling alignment. They do not expand beyond the general prophylaxis use; they partition it.
How do the XRPD peak definitions constrain infringement risk under U.S. 12,344,585?
Featured snippet answer: The patent’s key limitation is that the accused crystalline salt must exhibit XRPD peaks at specific 2θ values. Three peaks (5.3, 9.0, 22.0) are sufficient for Claim 1, while additional dependent claims demand larger peak lists (including 14.3, 16.2, 19.8, 21.2, 23.3, 24.6, 30.3) and allow FIG.-anchored “substantially similar” pattern evidence.
Practical read-through of the “±0.2°” window
Claim 1 defines the 2θ peaks with “±0.2°” tolerance. That tolerance is likely to be a focal point for:
- instrument differences (diffractometer geometry and calibration),
- sample prep differences (particle size, preferred orientation),
- measurement conditions (step size, scan range, temperature control).
If a competitor’s crystalline form shifts peak positions outside the ±0.2° band for one of the three anchors, Claim 1 may be avoided. However, “substantially similar” provisions in Claim 9 can complicate easy design-around.
Why the 3-peak minimum matters
Claim 1’s three anchors are a relatively low “information density” requirement versus the expanded peak-set dependent claims. This increases the likelihood that multiple solid forms of Compound I could accidentally overlap those three peak positions. The legal boundary then becomes whether the accused salt still satisfies the claimed bis(hydrochloride) identity and the broader “substantially similar” fingerprints.
Why dependent claims 5–8 create a stronger net
Claims 5 and 7 require additional peaks. Even if a competitor matches the core three-peak pattern, failing to reproduce one or more of the additional peaks could remove exposure under those dependent claims while leaving exposure under Claim 1.
Role of “XRPD substantially similar to FIG. 1”
Claim 9 does not enumerate peak lists. It ties infringement to comparison of the observed pattern against a reference figure. This increases litigation leverage because the reference figure typically becomes:
- a template for qualitative and semi-quantitative assessment,
- a basis for expert testimony on pattern similarity metrics.
TGA-IR in Claim 10: secondary confirmation
Claim 10 adds a thermogravimetric-infrared characterization requirement “substantially as shown in FIG. 2.” This:
- does not replace XRPD limitations in Claim 1, because it is a dependent claim,
- but can be used to confirm solid-state identity, especially where XRPD patterns are close.
What dosing and regimen limitations exist in U.S. Patent 12,344,585?
Featured snippet answer: The only regimen terms are oral once-daily administration and a dose window “about 125 mg to about 175 mg,” with dependent claims pegging the endpoints at about 125 mg and about 175 mg.
Claim 1 regimen boundaries
- Once-daily is explicit. A competitor whose protocol uses a different frequency would be outside the literal “once a day” limitation.
- Dose window: “from about 125 mg to about 175 mg.” “About” introduces flexibility for minor rounding.
- Oral route is explicit. Parenteral dosing should not meet literal scope.
How the endpoint claims strengthen enforcement
Claims 2 and 3 cover exactly the practical extremes. That matters where a commercial product might be labeled as one of those endpoints (for example, 125 mg or 175 mg tablets), because infringement arguments become tied to label-directed dosing rather than general ranges.
Which hereditary angioedema populations are covered by U.S. 12,344,585?
Featured snippet answer: The patent covers prophylaxis to prevent HAE attacks broadly, and dependent claims additionally specify HAE type I and type II.
- Independent claim: “hereditary angioedema” without subtype restriction.
- Dependent claim 11: type I.
- Dependent claim 12: type II.
If a product is indicated only for one subtype, enforcement can be aligned to the specific dependent claim, but Claim 1 still covers any HAE patient population if the specific subtype element is not required by the claim asserted.
What is the patent estate structure implied by the claim set?
Featured snippet answer: The claim set suggests a solid-form patent anchored to a particular crystalline salt identity (bis(hydrochloride) of Compound I) with XRPD-defined polymorph/solvate form. Dependent claims ladder from minimum XRPD fingerprinting to broader FIG.-anchored similarity, plus a secondary TGA-IR confirmation and dose endpoints.
Likely claim-family pattern (based on what is claimed)
Although the exact filing history and related patents are not provided, the internal structure is consistent with a family that typically includes:
- a foundational salt/form crystallinity claim (here: Claim 1),
- additional crystalline form characterization claims (Claims 5–10),
- use claims for prophylaxis in HAE and subtype limitations (Claims 11–12),
- dosage range and endpoint claims (Claims 1–3).
This structure often creates two litigation tracks:
- disputes on analytical identity (XRPD peak matching, “substantially similar”),
- disputes on regimen and dose mapping (once-daily and 125–175 mg).
What freedom-to-operate design-around options exist against U.S. 12,344,585?
Featured snippet answer: The clearest design-around levers are (1) changing the solid form so XRPD anchor peaks at 5.3, 9.0, and 22.0 (±0.2°) do not match simultaneously, (2) changing dosing frequency away from once-daily and/or shifting out of the 125–175 mg range, (3) using a non-bis(hydrochloride) salt, and (4) avoiding matching FIG. 1 “substantially similar” and FIG. 2 TGA-IR fingerprints.
- Switch salt form: avoid bis(hydrochloride). If Compound I is used as a different salt, Claim 1’s salt identity fails.
- Avoid the crystalline form: pick a polymorph or hydrate that does not reproduce the claimed XRPD peak pattern within the tolerance window.
- Avoid the regimen: change from once-daily dosing or shift dose outside the claimed “about 125 mg to about 175 mg.”
- Avoid fingerprint similarity: even if peak enumeration overlaps, FIG.-based “substantially similar” could still be asserted.
Because Claim 1 has a minimal three-peak requirement, the most effective design-around is likely solid-form divergence that breaks at least one of the three anchor peaks within ±0.2° under comparable test conditions.
What patent landscape coverage issues arise without knowing Compound I identity?
Featured snippet answer: The claim language is Compound-I agnostic, but the enforcement profile is dominated by the crystalline bis(hydrochloride) solid form and by XRPD peaks tied to FIG. 1 and FIG. 2. Without the definition of Compound I and its broader patent families, the full landscape cannot be mapped to specific prior art salts or related polymorph filings.
Key Takeaways
- Core scope: once-daily oral prophylaxis for hereditary angioedema using a crystalline bis(hydrochloride) salt of Compound I.
- Critical limitation: XRPD peaks at 2θ 5.3, 9.0, and 22.0 with ±0.2° tolerance (Claim 1), with dependent claims adding larger peak sets.
- Dose lock: about 125 mg to about 175 mg, plus dependent claims at about 125 mg and about 175 mg.
- Solid-form proof: Claim 9 ties infringement to FIG. 1 “substantially similar” XRPD; Claim 10 ties it to FIG. 2 TGA-IR.
- HAE targeting: dependent claims cover type I and type II.
FAQs
1) What XRPD peaks matter most for infringement under U.S. 12,344,585?
Claim 1 requires XRPD peaks at 2θ 5.3, 9.0, and 22.0 (±0.2°); dependent claims require additional peaks beyond those anchors.
2) Does the patent cover parenteral dosing?
No, the claims require oral administration and once daily.
3) Can a competitor avoid the patent by changing only dose within 125–175 mg?
If dosing remains within about 125–175 mg and the same solid form is used, the dose variation may still fall within Claim 1. Claims 2 and 3 cover the endpoints.
4) What is the legal significance of “substantially similar” XRPD to FIG. 1?
It enables infringement arguments based on qualitative pattern similarity rather than only enumerated peaks, increasing reliance on expert comparison against the figure reference.
5) Do the type I/type II claims expand beyond the general HAE prophylaxis claim?
No. They are narrower dependent claims that specify HAE subtype; Claim 1 already covers hereditary angioedema prophylaxis in general.
References (APA)
- U.S. Patent No. 12,344,585, Claims 1–12 (provided).
